Document is current
Any future updates will be listed below
-
Authors
Sazonovs, Aleksejs
Stevens, Christine R. https://orcid.org/0000-0002-2621-2234
Venkataraman, Guhan R. https://orcid.org/0000-0003-0754-6631
Yuan, Kai https://orcid.org/0000-0002-8460-6581
Avila, Brandon
Abreu, Maria T.
Ahmad, Tariq
Allez, Matthieu
Ananthakrishnan, Ashwin N.
Atzmon, Gil
Baras, Aris
Barrett, Jeffrey C.
Barzilai, Nir
Beaugerie, Laurent
Beecham, Ashley
Bernstein, Charles N.
Bitton, Alain
Bokemeyer, Bernd
Chan, Andrew
Chung, Daniel
Cleynen, Isabelle
Cosnes, Jacques
Cutler, David J.
Daly, Allan
Damas, Oriana M.
Datta, Lisa W.
Dawany, Noor
Devoto, Marcella
Dodge, Sheila
Ellinghaus, Eva
Fachal, Laura
Farkkila, Martti
Faubion, William
Ferreira, Manuel
Franchimont, Denis
Gabriel, Stacey B.
Ge, Tian
Georges, Michel
Gettler, Kyle
Giri, Mamta
Glaser, Benjamin
Goerg, Siegfried
Goyette, Philippe
Graham, Daniel
Hämäläinen, Eija
Haritunians, Talin
Heap, Graham A.
Hiltunen, Mikko
Hoeppner, Marc
Horowitz, Julie E.
Irving, Peter
Iyer, Vivek
Jalas, Chaim
Kelsen, Judith
Khalili, Hamed
Kirschner, Barbara S.
Kontula, Kimmo
Koskela, Jukka T.
Kugathasan, Subra
Kupcinskas, Juozas
Lamb, Christopher A. https://orcid.org/0000-0002-7271-4956
Laudes, Matthias
Lévesque, Chloé
Levine, Adam P.
Lewis, James D.
Liefferinckx, Claire
Loescher, Britt-Sabina
Louis, Edouard
Mansfield, John
May, Sandra
McCauley, Jacob L.
Mengesha, Emebet
Mni, Myriam
Moayyedi, Paul
Moran, Christopher J.
Newberry, Rodney D.
O’Charoen, Sirimon
Okou, David T.
Oldenburg, Bas
Ostrer, Harry
Palotie, Aarno
Paquette, Jean
Pekow, Joel
Peter, Inga
Pierik, Marieke J.
Ponsioen, Cyriel Y.
Pontikos, Nikolas
Prescott, Natalie
Pulver, Ann E.
Rahmouni, Souad
Rice, Daniel L.
Saavalainen, Päivi
Sands, Bruce
Sartor, R. Balfour
Schiff, Elena R.
Schreiber, Stefan
Schumm, L. Philip
Segal, Anthony W.
Seksik, Philippe
Shawky, Rasha
Sheikh, Shehzad Z.
Silverberg, Mark S.
Simmons, Alison
Skeiceviciene, Jurgita
Sokol, Harry
Solomonson, Matthew
Somineni, Hari
Sun, Dylan
Targan, Stephan
Turner, Dan
Uhlig, Holm H.
van der Meulen, Andrea E.
Vermeire, Séverine
Verstockt, Sare
Voskuil, Michiel D.
Winter, Harland S.
Young, Justine
,
,
,
,
,
,
,
,
,
Duerr, Richard H.
Franke, Andre
Brant, Steven R.
Cho, Judy
Weersma, Rinse K.
Parkes, Miles
Xavier, Ramnik J.
Rivas, Manuel A.
Rioux, John D.
McGovern, Dermot P. B.
Huang, Hailiang
Anderson, Carl A.
Daly, Mark J.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (U54HG003067, 5UM1HG008895)
- License Information
-
More Information
Article History
Received: 1 July 2021
Accepted: 12 July 2022
First Online: 29 August 2022
Competing interests
: A. Baras., M. Ferreira., J.E.H. and D.S are current or former employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. M.A. is consulting for or part of the advisory board for AbbVie Inc., Bellatrix Pharmaceuticals, Bristol Myers Squibb, Eli Lilly Pharmaceuticals, Gilead, Janssen Ortho, LLC, and Prometheus Biosciences; and teaching, lecturing or speaking at Alimentiv, Arena Pharmaceuticals, Janssen, Prime CME, Takeda Pharmaceuticals. A.B. is an employee of Regeneron and owns stock in Regeneron. O.M.D. has served in the IBD fellowship funding committee for Pfizer and has a funded research project by Pfizer. H.K. receives grant funding from Takeda and Pfizer and has received consulting fees from Takeda. A.P. is a member of Astra Zenecas Genomics Advisory Board. M.A.R. is on the SAB of 54gene and has advised BioMarin, Third Rock Ventures, MazeTx and Related Sciences. G.A.H. is an employee of Takeda, former employee of AbbVie and owns stock in Takeda and AbbVie. C.A.L. reports grants from Genentech, grants and personal fees from Janssen, grants and personal fees from Takeda, grants from AbbVie, personal fees from Ferring, grants from Eli Lilly, grants from Pfizer, grants from Roche, grants from UCB Biopharma, grants from Sanofi Aventis, grants from Biogen IDEC, grants from Orion OYJ, personal fees from Dr Falk Pharma and grants from AstraZeneca, outside the submitted work. H.H.U. reports research collaboration or consultancy with Janssen, Eli Lilly, UCB Pharma, Celgene, MiroBio, OMass and Mestag. D.P.B.M. has consulted for Takeda, Boehringer Ingelheim, Palatin Technologies, Bridge Biotherapeutics, Pfizer and Gilead. M.P. received an unrestricted research grant from Pfizer UK and speaker fees from Janssen. P.I. received lecture fees from AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire and Warner Chilcott; financial support for research from Celltrion, MSD, Pfizer and Takeda; advisory fees from AbbVie, Arena, Boehringer Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma and Warner Chilcott. Cedars-Sinai and D.P.B.M. have financial interests in Prometheus Biosciences, a company which has access to the data and specimens in Cedars-Sinais MIRIAD Biobank (including the Cedars-Sinai data and specimens used in this study) and seeks to develop commercial products. H.H. has received consultancy fees from Ono Pharmaceutical and honoraria from Xian Janssen Pharmaceutical. C.A.A. has received consultancy fees from Genomics plc and BridgeBio Inc. and lecture fees from GSK. M.J.D. is a founder of Maze Therapeutics. The remaining authors declare no competing interests.
